Insider Sell: BioXcel Therapeutics
12:39AM ET 3/23/2023 MT NewswiresVimal Mehta, Director, Chief Executive Officer and President, on March 20, 2023, sold 64,500 shares in BioXcel Therapeutics (BTAI) for $1,223,313....
Vimal Mehta, Director, Chief Executive Officer and President, on March 20, 2023, sold 64,500 shares in BioXcel Therapeutics (BTAI) for $1,223,313....
BioXcel Therapeutics (BTAI) has an average rating of outperform and price targets ranging from $22 to $82, according to analysts polled by Capital IQ. (MT...
BioXcel Therapeutics (BTAI) has an average rating of Outperform and price targets ranging from $22 to $82, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
BioXcel Therapeutics (BTAI) reported a Q4 loss Thursday of $1.95 per share, wider than a loss of $0.93 a year earlier. Analysts polled by Capital IQ...
BioXcel Therapeutics (BTAI) has an average buy rating and price target range of $20 to $82, according to analysts polled by Capital IQ. (MT Newswires...
BioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $20 to $82, according to analysts polled by Capital IQ. (MT...
BioXcel Therapeutics (BTAI) said late Monday its phase 2 trial testing the combination of BXCL701 and Merck's (MRK) Keytruda in castration-resistant...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Karuna Therapeutics (KRTX) said Tuesday that it has named Will Kane chief commercial officer, effective Feb. 6. Kane has previously served as executive...